Barclays Maintains Overweight on Viatris, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 85.5%

Neg 0% Neu 0% Pos 85.5%

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $15 to $17.